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Abstract
Purpose Microsatellite instability (MSI) and mismatch repair
(MMR) gene expression present a hallmark mutational signa-
ture of Lynch syndrome as a common hereditary cancer pre-
disposing condition. Since there is not enough data of molec-
ular and clinicopathological aspects of the disease in Iranian
populations, this article is a new description in Central Iran.
Methods It is a descriptive analytical study in which we
screened 1659 colorectal cancer (CRC) patients based on
early-onset disease and Amsterdam II criteria during 14 years
(2000–2013). MSI testing was applied through a commercial
kit evaluating five mononucleotide markers (BAT-25, BAT-
26, MON0-27, NR-21, and NR-24) using a fluorescent mul-
tiplex PCR method. Immunohistochemistry (IHC) staining
was set up to detect expression of four mismatch repair
(MMR) genes including MLH1, MSH2, MSH6, and PMS2.
SPSS 16 software was used to analyze the data.
Results Overall, 31 of 45 screened at-risk families were even-
tually included to MSI testing of which 9/31 patients (∼29 %)
showed MSI in their tumor tissues including 6 (19.4 %) MSI-
H (high). BAT-26 was the most instable marker with instabil-
ity in 7/31 MSI tumors (22.6 %). IHC-MMR staining was
absent in 7/31 probands (22.6 %) of which in 4 cases, both
MSH2/MSH6 (57.1 %) and, in 2 cases, both MLH1/PMS2
showed deficiency (28.6 %), and just in one case, MSH6 was
defective (14.3 %). IHC-MMR was absent in all 6 MSI-H
tumors while none of 3 MSI-L tumors were MMR-deficient.
Just single MSH6-defective tumor showed MSS state. The
frequency of CRC among MMR-deficient and MMR-
proficient families was 67.5 and 27.9 %, respectively. The
most common extracolonic cancer among both MMR-
deficient and MMR-proficient groups was stomach, respec-
tively, with 26.7 and 16.5 %.
Conclusions A different molecular and clinicopathological
phenotype of tumors in CRC Iranian patients at risk for
Lynch syndrome could suggest some new molecular mecha-
nisms about which more evaluations are necessary.
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Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC) or
Lynch syndrome (LS) is a cancer susceptibility syndrome sec-
ondary to a germline mutation in at least one of the DNA
mismatch repair genes (MMRs) including MLH1, MSH2,
MSH6, and PMS2 [1]. It leads to accumulate of mutations in
other genes responsible to apoptosis and cell cycle control
which accelerate some tumorigenesis events [2, 3]. Mutation
analysis of MMRs is both time-consuming and expensive be-
cause of so heterogeneous mutations in these genes [4]. Two
molecular screening tools are commonly being used to detect
LS, including microsatellite instability (MSI) testing and im-
munohistochemical (IHC) staining of MMR proteins.
MSI refers to genomic instability of short tandem repeats
(STRs), the stretched sequences of 1–5 base pairs repeating
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units with 25–60 bp in length distributed throughout the ge-
nome [5]. Actually, MSI is a mutational signature or a molec-
ular fingerprinting [6], the hallmark of CRC concluded from
DNAmismatch repair system deficiency [7]. MSI is identified
as a change in allele size between tumor and normal DNA. It is
found in almost 15–24 % of all CRCs [8] while in LS, includ-
ing nearly 3% of all CRCs, about all cases showMSI in tumor
cells [7]. This contains 20–25% of all MSI-CRCs. OtherMSI-
CRCs (75–80 %) are concluded from an epigenetic DNA-
MMR deficiency due to the promoter hypermethylation of
the MLH1 gene [9]. Although MSI has enough sensitivity to
identify LS, it will not be detected in about 5 % of the all LS
tumors [10]. A fluorescent multiplex PCR-based method is
currently applied for MSI testing. A pentaplex panel including
mononucleotide repeats has had a sensitivity more than 95 %
and specificity more than 98 % to identify CRC tumors with
MMR deficiency [11].
MMR deficiency can be also detected using IHC staining
in tumor sections; so, proficient nuclear staining implies the
normal expression of MMR genes (IHC-present), and absent
nuclear staining indicates the loss of MMR gene expression
(MMR-deficiency). IHC has been reproduced as the comple-
ment of MSI-testing [10, 12], although it has been advised by
some authors as the first screening method before genetic
testing because of some advantages compared to MSI-
testing [13]. IHC is more accessible than MSI as a routine
service in the most pathology laboratories and a proficient,
viable procedure at the time of colectomy [14]. Moreover,
IHC is more inexpensive than MSI [15] being considered as
a genetic testing by which a defective MMR gene would be
recognized leading to efficient mutation analysis of the target
gene [16, 17]. IHC-MMRs, however, have some limitations
such as uncertainty in interpretation and low sensitivity to
discover mutation ofMLH1 with MLH1 antibody alone [16].
CRC is the third most prevalent leading cause of cancer-
related deaths in Iran [18], and its incidence has been in-
creased over the last three decades in the country [19].
However, no systematic screening program has been set up
so far in Iran to detect and evaluate hereditary colorectal can-
cer. Therefore, our study is a new trial to set up a screening
system in center of Iran (Isfahan).
Materials and Methods
Study Design
A descriptive retrospective study was designed to select CRC
patients at risk for Lynch syndrome in Central Iran. Among
1659 CRC patients registered in Poursina Hakim Research
Center (PHRC), an important referral gastroenterology clinic
in Central Iran, within 2000–2013, we at first selected all
early-onset patients (patients with age ≤50). Then, we used
Amsterdam II criteria for primary clinical screening including
the following: having at least 3 affected members with one of
the HNPCC-associated cancers (CRC, other GI cancers, en-
dometrial, renal, breast (according to some resources), brain,
skin, and pelvic cancers) in at least two successive genera-
tions, and one of these three members being a first degree
relative of the other two and at least one diagnosed before
the age of 50 years.
MSI Testing
Both tumor and normal tissue DNA are necessary for MSI
testing. Although a pentaplex panel including two mononu-
cleotide markers (BAT25 and BAT26) and three dinucleotide
markers (D2S123, D5S346, and D17S250) is currently rec-
ommended by NCI, the National Cancer Institute, to analyze
MSI [11, 20], the pentamerous mononucleotide markers have
shown a higher specificity and similar or better sensitivity than
dinucelotide markers to detect an MSI-H phenotype [21, 22].
We used a commercial kit from Promega (MSI Analysis
System, Version 1.2) by which five mononucleotide markers
(BAT-25, BAT-26, MON0-27, NR-21, and NR-24) are evalu-
ated. It also contains two pentanucleotide markers (Penta C
and Penta D) as specimen detector markers to identify speci-
menmix-ups. Themarkers are amplified through a fluorescent
multiplex PCR-based method. Then, the amplified alleles are
evaluated in matching pairs of test samples, which may be
MMR-deficient and normal tissue samples. If new alleles are
observed in the tumor sample without their presence in the
corresponding normal sample, MSI is confirmed. Tumors
would be considered as MSI-High (MSI-H) if at least two of
five quasimononucleotide markers show instability and MSI-
low (MSI-L) if only one marker is unstable.
Immunohistochemistry
A formalin-fixed paraffin-embedded (FFPE) tissue block is
necessary for IHC on each case preferably from resected bow-
el specimen included tumoral and adjacent normal mucosa.
After cutting the block and preparing at least four slides per
case to evaluate four MMR proteins, the slides are incubated
with Protein Block reagent and primary antibodies according
to IHC guideline specific for each immunologic product.
Then, they are incubated with Post Primary Block reagent
for several minutes. In each step, the slides must be washed
in TBS with gentle rocking for a short moment. The next step
is developing peroxidase activity with DAB working solution
for some minutes. Then, the slides are counterstained with
hematoxylin and finally dehydrated, cleared, and mounted.
Our slides were ready at the time for microscopic observation.
If the MMR protein has been expressed, the nuclear staining
will be present. MMR deficiency leads to absent nuclear stain-
ing in tumor section compared to normal adjacent tissue.
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Data Analysis
We analyzed the obtained data by SPSS 16 software package
(SPSS Inc., Chicago, IL, USA).
Informed Consent
Informed consent was obtained from all individual partici-
pants included in the study.
Results
Altogether, 413 patients (24.9 %) were identified as early on-
set (age ≤50 years at diagnosis) after screening of 1659 CRC
patients registered in PHRC within a 14-year period (2000–
2013). Among 219/413 successful calls, 45 HNPCC families
met finally Amsterdam II criteria and were candidate for mo-
lecular analyses of which 14 probands were excluded due to
lack of their tumor tissues or being unwilling for
incorporation.
Altogether, 9 of 31 studied HNPCC probands (∼29 %)
showed MSI in their tumor tissues (6 patients (19.4 %) with
MSI-H). Male to female proportion in MSS probands was 11/
11=1, and in MSI probands, it was 6/3=2. BAT-26 was the
most instable quasimononucleotide marker with instability in
7/31 MSI tumors (22.6 %). In 6/31 cases (19.3 %), both BAT-
25 and NR-24markers showed instability, and bothMONO-27
and NR-21 markers were instable in 5/31 (16.1 %) MSI-CRC
tumors. All markers were instable (66.6 %) in 4/6 MSI-H pa-
tients, and among two rest patients, one showed instability in
four markers (except MONO-27) and the other showed insta-
bility in two of them (BAT-26 and NR-24) (Figs. 1, 2, and 3).
IHC-MMR staining was absent in 7/31 probands (22.6 %)
of which 4 cases wereMMR-deficient (IHC-A) in bothMSH2
and MSH6 (57.1 %), in 2 cases, both MLH1 and PMS2 had
negative staining (28.6 %), and just in one case, MSH6 was
defective (14.3 %). IHC-MMR staining was absent in all 6
MSI-H tumors while none of 3 MSI-L tumors were MMR-
deficient. Among all IHC-MMR absent tumors, just single
MSH6-defective tumor showed MSS state (4.5 %).
The age of MMR-deficient probands at diagnosis was av-
eragely 38.0 years (range 31–50), while MMR-proficient pro-
bands had averagely 45.3 years at diagnosis (range 24–50) (P
value <0.05).
There was a positive history of cancer in 186 members
within 31 HNPCC families of which 140 affected members
were in 24 MMR-proficient families and 46 cancer patients in
7 MMR-deficient families. The mean age of cancer patients
among MMR-proficient and MMR-deficient families was
51.7 and 51.0, respectively (P value=0.817).
The most frequent tumor sites among MMR-deficient pro-
bands were as follows: rectum (41.7 %), sigmoid colon
(33.3 %), cecum (12.5 %), and ascending colon (8.3%); while
among MMR-proficient probands were as follows: ascending
colon and descending colon (28.6 %) and transverse colon,
sigmoid colon, and cecum (each one 14.3 %) were the most
common involved sites. Meanwhile, there was no case with
rectum involvement among MMR-deficient probands
(Table 1).
The most frequent cancers among MMR-deficient families
were as follows: CRC (67.4 %), stomach (8.7 %), hematopoi-
etic system (6.5 %), and prostate, hepatobiliary tract, and lung
(4.3 %), while in MMR-proficient families, CRC (39.3 %),
stomach (10 %), lung (8.6 %), breast (7.9 %), and brain
(6.4 %) were the most common cancers (Table 2).
Although 1 of 7 MMR-deficient probands (∼14 %) was
diagnosed at I or II pathological TNM stage, a third of
MMR-proficient probands (8/24∼33 %) were found at these
early stages (Table 3). On the other hand, 11/24 of MMR-
proficient probands (∼46 %) had been deceased at the screen-
ing time while 6/7 of MMR-deficient probands (∼86 %) were
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Fig. 1 Frequency of five
quasimononucleotide markers in
31 Amsterdam positive tumors
according to instability state
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alive at this time. The survival period of the probands, the
interval between diagnosis time, and date of death or date of
analysis were averagely calculated for MSS,MSI-L, andMSI-
H group of the probands as 6.1, 2.0, and 5.8 years, respective-
ly (P value=0.341).
Discussion
We used being early-onset disease (age at diagnosis ≤50 years)
and Amsterdam II criteria, simultaneously, to primary selec-
tion of our samples. Somewhat, high prevalence of familial
Fig. 2 An example of
microsatellite instability in one of
our DNA electropherogram trace:
It is related to three
quasimononucleotide markers
including NR-21, BAT-25, and
MONO-27, indicating normal
stability state in upper sample
(153455 5) as normal healthy
tissue, and instability state in
every three markers in lower
sample (153456 6) as tumor tissue
Fig. 3 A positive
immunohistochemical staining of
paraffin-embedded colorectal
cancer tissue using MSH2
antibody at dilution of 1:100
(under ×40 lens)
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CRC among our population and the limitation of our financial
resources made us using these more stringent specific criteria.
Microsatellite Instability Analysis
According to instability rate among five quasimononucleotide
markers of pentaplex Promega panel in our MSI-CRC tumors,
16.1 to 22.6 %, apparently all of these five markers were
determinant to detect MSI status of our probands. In different
studies, however, variable molecular phenotypes for these
markers have been described. For example, in a recent
Iranian study on 80 sporadic CRC patients, the most instable
markers were NR-21, NR-24 with 45 %. In this study, NR-27
with zero and BAT-26 with 6.7 % instability were the most
stable markers [23]. Also, in another Iranian study on 80 spo-
radic CRC and 80HNPCC patients, NR-21 was determined as
the mos t f r equen t ins t ab l e marke r among f ive
quasimonomorphic markers with 53 and 25.6 % in sporadic
CRC and HNPCC tumors, respectively. NR-27 was also de-
termined as the most stable marker with 0 and 19.2 % in
sporadic CRC and HNPCC tumors, respectively [24]. In the
only performed study on MSI testing in HNPCC patients in
Isfahan, just BAT-26marker was analyzed in blood samples of
40 HNPCC patients of which 12 cases (30 %) showed insta-
bility [25]. Since no specific clinicopathological criteria have
been mentioned to screen the patients in the study and just
blood DNA has been tested, apparently, we cannot compare
our results to their findings. Other similar studies among dif-
ferent ethnic populations around the world have shown vari-
ous results [26–28]. It seems that instability feature of mono-
nucleotide markers varies among different populations due to
ethnical variation in frequency of these markers. It may be also
variable in sporadic CRCs compared to LS-CRCs, an issue
about which more evaluations on larger samples are
necessary.
Immunohistochemistry of MMR Proteins
Given the high sensitivity of simultaneous usage of both IHC
and MSI testing to identify MMR deficiency [29], apparently,
a significant portion of Amsterdam positive families in our
population has no MMR mutations. It highlights the role of
other genes in etiology of the most our samples. Although
there is no explicit data of Iranian population, according to
other studies, about 35–70 % of HNPCC families meeting
Amsterdam criteria do not have MMR deficiency and are
considered BFamilial Colorectal Cancer Type X^ (FCC-X)
or Bnon-syndromic familial colorectal cancer^ [30, 31].
More studies on larger samples using complementary tech-
niques such as mutation analyses could estimate a more accu-
rate prevalence of FCC-X among Iranian population.
MSH6 and PMS2 proteins are accessory to major MMR
proteins: MSH2 and MLH1, respectively. So, the loss of
MSH2 expression in a tumor tissue leads to loss of MSH6
expression in that tissue. Germline mutations, however, in
MSH6 or PMS2, as minor MMR genes, lead to single loss of
expression of their associated proteins [2]. Consequently,
MSH2 was responsible gene in 57 % of the MMR-deficient
cases. The frequency ofMSH2 defect in our study was similar
to some large early studies [32]. MMR-deficiency for both
MLH1 and PMS2 proteins in about 29 % of the tumors
Table 1 Frequency of tumor sites in Iranian colorectal cancer patients
at risk for LS in both MMR deficient and MMR proficient groups
Tumor site MMR-proficient families MMR-deficient families
Frequency Percent Frequency Percent
Cecum 3 12.5 1 14.3
Ascending colon 2 8.3 2 28.6
Transverse colon 0 0.0 1 14.3
Descending colon 0 0.0 2 28.6
Sigmoid colon 8 33.3 1 14.3
Rectum 10 41.7 0 0.0
Unknown 1 4.2 0 0.0
Total 24 100.0 7 100.0
LS Lynch syndrome, MMR mismatch repair genes
Table 2 Frequency of cancer locations among Iranian colorectal cancer
patients at risk for LS in both MMR-deficient and MMR-proficient
groups
Cancer type MMR proficient MMR deficient Sum
Frequency Percent Frequency Percent
CRC 55 39.3 31 67.4 86
GC 14 10.0 4 8.7 18
Lung 12 8.6 2 4.3 14
Breast 11 7.9 1 2.2 12
Brain 9 6.4 0 0.0 9
HBC 7 5.0 2 4.3 9
Intestine 6 4.3 0 0.0 6
Prostate 4 2.9 2 4.3 6
Uterus 4 2.9 1 2.2 5
Skin 3 2.1 0 0.0 3
HP 3 2.1 3 6.5 6
Bladder 3 2.1 0 0.0 3
Thyroid 2 1.4 0 0.0 2
Testis 2 1.4 0 0.0 2
Bone 2 1.4 0 0.0 2
Kidney 1 0.7 0 0.0 1
Pancreas 1 0.7 0 0.0 1
Nasopharynx 1 0.7 0 0.0 1
Total 140 100 46 100 186
LS Lynch syndrome, MMR mismatch repair genes
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predicts existence of germline mutation in MLH1 of near to
30 % of the MMR-deficient probands. It is comparable to
some early valid studies [33]; however, developing the results
by mutation analyses, preferably on a larger sample, will be
more informative. Since individual PMS2 loss in IHC-
staining is the rarest event [34], we identified also no proband
with absent IHC-staining for PMS2.
Although all our MMR-deficient cases showed MSI-H in
MSI testing for main MLH1 and MSH2 antibodies, the single
IHC-MSH6 absent case presented MSS (14.3 %). Some mu-
tations in MSH6 gene may not be identified by MSI testing. It
is due to the secondary nature of MSH6 protein in MutS com-
plexes in which functional redundancy of this protein with
MSH3, another accessory MMR protein, could explain MSS
or MSI-L phenotype of the tumor, at least in some cases [18,
35].
Phenotype–Genotype Correlation
Genetic pedigree related to MSH6-defective proband shows
fewer affected relatives than MSH2/MLH1-defective pro-
bands (3 versus 6.5 cases, averagely). According to some
studies, we expect that the patients with MSH6 mutations
would be more likely Amsterdam negative [36]; so, the
Bethesda guidelines are more sensitive than the Amsterdam
Criteria to identify it [20]. Consequently, we may find more
MSH6-defective patients among all our CRC patients using
Bethesda guidelines.
Age at diagnosis in MMR-deficient probands was average-
ly more than 7 years earlier than probands without MMR-
deficiency (38 versus 45.3 years) (P value <0.05).
Meanwhile, there was nomeaningful difference between other
cancer patients in both groups of families (51 versus
51.7 years) (P value=0.817).
Mean age at diagnosis in the patients with MLH1 deficien-
cy was 8 years earlier than the MSH2-deficient patients (∼42
versus ∼50 years old, P value <0.01). Moreover, there were
more extracolonic cancer types among the MSH2-deficient
families compared to the families with MLH1 or MSH6 de-
fects (7 types versus 4 and 2 types, respectively). A genotype–
phenotype correlation has been reported in MMR mutation
carriers. For example, MLH1 mutations are related to higher
risk of early-onset CRC cancer and more prevalent CRC can-
cer than extracolonic cancers, while in MSH2 mutation car-
riers, there is a higher risk of multiple extracolonic cancers,
and the mean age of diagnosis is more than MLH1 mutation
carriers [37, 38] .
Mean age of three cancer patients at diagnosis in the single
MSH6-deficient family was about 67 years, averagely two
decades later than the patients in families with MLH1 or
MSH2 defects. The proportion of CRC patients in this family
was also considerably lower than LS families with MSH2 or
MLH1 defects (33 % versus 72 and 66 %, respectively).
MSH6mutations present a phenotype somewhat different than
MLH1 and MSH2 mutations; so, this condition has been de-
scribed as BMSH6 syndrome^ [36]. Mean age at cancer diag-
nosis in MSH6 mutation carriers is at least one decade more
than MSH2 or MLH1 mutation carriers [37]. In addition, the
risk of CRC affection in families with MSH6 defect is more
likely less than LS families withMSH2 orMLH1 defects [39].
Some studies have shown that CRC risk among FCC-X fam-
ilies is lower than HNPCC families. Also, CRC diagnosis has
occurred averagely 10–15 years later in FCC-X families [26,
40].
According to our findings, 57.1 and 20.8 % of our index
CRCswith and withoutMMR deficiency were localized prox-
imal to the splenic flexure, respectively (P<0.01). More stud-
ies on families with Amsterdam criteria that have shown a
higher proportion of CRCs are located proximal to the splenic
flexure in patients with MMR deficiency than those with pro-
ficient MMRs [40–42].
Although there was no meaningful difference between av-
erage count of cancer patients among families in both MMR-
deficient and proficient groups (6.6 versus 5.8, P value=
0.513), the relative frequency of CRC to all cancer patients
among MMR-deficient families was mainly more than fami-
lies without MMR deficiency, nearly 2.5-fold (67.5 versus
27.9 %). Meanwhile, we had asked cancer-related family his-
tory up to three generations in both groups.
The proportion of the survivors at screening in MMR-
deficient group to proficient one was about 2-fold.
Meanwhile, the early-stage diagnosis among MMR-
Table 3 Frequency of TNM pathological stage at diagnosis time among Iranian colorectal cancer patients at risk for LS in both MMR-deficient and
MMR-proficient groups
MMR genes function Stage I Stage II Stage III Stage IV Total
Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent
Deficient 7 29.2 1 4.2 11 45.8 5 20.8 24 100
Proficient 0 0.0 1 14.3 5 71.4 1 14.3 7 100
Total 7 22.6 2 6.5 16 51.6 6 19.4 31 100
LS Lynch syndrome, MMR mismatch repair genes
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proficient group was more than 2-fold of MMR-deficient pro-
bands, according to their pathological documents. It may refer
to better survival of MSI-CRCs compared to MSS CRCs, a
fact that has been considered in some studies [43].
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